IP Library Granted Patent US 10,519,465
Granted Patent B2
US 10,519,465 · App. 16/153,433 · Granted Dec 31, 2019

Tissue selective transgene expression

Inventors: Stephanie Tagliatela (South San Francisco, CA); Andrew Young (South San Francisco, CA); Szu-Ying Chen (South San Francisco, CA); Kartik Ramamoorthi (South San Francisco, CA); David Oberkofler (South San Francisco, CA)
Assignee: Encoded Therapeutics, Inc.
C12N15/85A61K48/0058C12N15/113C12N15/86C12N15/8645A61K48/00C12N2320/32C12N2750/14143C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,519,465
App. No.
16/153,433
Filed
Oct 5, 2018
Granted
Dec 31, 2019
Kind
B2
Art Unit
1633
USPC
435/320.1
Abstract

Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.

Claims (13)

1. A nucleic acid cassette comprising a regulatory element comprising SEQ ID NO: 30 operably linked to a transgene.

2. The nucleic acid cassette of claim 1 , wherein the transgene comprises a nucleic acid sequence encoding a DNA binding protein.

3. The nucleic acid cassette of claim 2 , wherein the DNA binding protein is a transcriptional modulator of an endogenous gene.

4. The nucleic acid cassette of claim 2 , wherein the DNA binding protein comprises a zinc finger.

5. The nucleic acid cassette of claim 2 , wherein the DNA binding protein is a nuclease-deactivated zinc finger protein.

6. The nucleic acid cassette of claim 2 , wherein the DNA binding protein is linked to a transcriptional activator domain.

7. The nucleic acid cassette of claim 2 , wherein the DNA binding protein is linked to a transcriptional repressor domain.

8. The nucleic acid cassette of claim 2 , wherein the DNA binding protein is a transcriptional activator that modulates an endogenous SCN1A gene.

9. The nucleic acid cassette of claim 1 , wherein the nucleic acid cassette is an adeno-associated virus (AAV) vector.

10. The nucleic acid cassette of claim 9 , wherein the AAV vector is AAV9 or scAAV9.

11. The nucleic acid cassette of claim 8 , wherein the nucleic acid cassette is an adeno-associated virus (AAV) vector.

12. The nucleic acid cassette of claim 11 , wherein the AAV vector is AAV9.

13. The nucleic acid cassette of claim 11 , wherein the AAV vector is scAAV9.

Assignments (2)
CHANGE OF NAME Recorded Feb 21, 2019
From: ENCODED GENOMICS, INC.
To: ENCODED THERAPEUTICS, INC.
Reel/Frame 048410/0988 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2019
From: TAGLIATELA, STEPHANIE; YOUNG, ANDREW; CHEN, SZU-YING; RAMAMOORTHI, KARTIK; OBERKOFLER, DAVID
To: ENCODED GENOMICS, INC.
Reel/Frame 048402/0792 →
Continuity (3)
Continuation PCTUS2018025940 · Apr 3, 2018
Provisional Application 62480998 · Apr 3, 2017
Related Publication 20190024120A1 · Jan 24, 2019
Cited By (2)
US 12,516,350 US 12,692,516